News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
686,259 Results
Type
Article (39078)
Company Profile (279)
Press Release (646902)
Section
Business (203876)
Career Advice (1992)
Deals (35364)
Drug Delivery (86)
Drug Development (80814)
Employer Resources (168)
FDA (16092)
Job Trends (14805)
News (344573)
Policy (32440)
Tag
Academia (2530)
Alliances (49111)
Alzheimer's disease (1239)
Approvals (16025)
Artificial intelligence (141)
Bankruptcy (352)
Best Places to Work (11548)
Biotechnology (200)
Breast cancer (135)
Cancer (1145)
Cardiovascular disease (103)
Career advice (1660)
Cell therapy (240)
Clinical research (64350)
Collaboration (407)
Compensation (211)
COVID-19 (2533)
C-suite (101)
Data (1175)
Diabetes (157)
Diagnostics (6156)
Earnings (84844)
Employer resources (146)
Events (109709)
Executive appointments (326)
FDA (16660)
Funding (372)
Gene therapy (182)
GLP-1 (581)
Government (4327)
Healthcare (18681)
Infectious disease (2619)
Inflammatory bowel disease (108)
Interviews (308)
IPO (16311)
Job creations (3624)
Job search strategy (1417)
Layoffs (414)
Legal (7854)
Lung cancer (174)
Manufacturing (179)
Medical device (13187)
Medtech (13192)
Mergers & acquisitions (19153)
Metabolic disorders (410)
Neuroscience (1527)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1539)
Obesity (234)
Opinion (179)
Patents (108)
People (56313)
Phase I (19992)
Phase II (28340)
Phase III (21133)
Pipeline (475)
Postmarket research (2555)
Preclinical (8504)
Radiopharmaceuticals (236)
Rare diseases (228)
Real estate (5890)
Regulatory (21561)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1335)
Startups (3562)
United States (13939)
Vaccines (553)
Weight loss (169)
Date
Today (108)
Last 7 days (381)
Last 30 days (3263)
Last 365 days (35503)
2024 (33365)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (193)
Asia (37170)
Australia (6065)
California (3449)
Canada (1336)
China (268)
Colorado (151)
Connecticut (159)
Europe (79583)
Florida (481)
Georgia (122)
Illinois (351)
Indiana (204)
Kansas (96)
Maryland (595)
Massachusetts (2711)
Michigan (160)
Minnesota (277)
New Jersey (992)
New York (996)
North Carolina (714)
Northern California (1539)
Ohio (142)
Pennsylvania (866)
South America (1091)
Southern California (1335)
Texas (495)
Utah (92)
Washington State (371)
686,259 Results for "sientra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Sientra, Inc. announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024.
February 13, 2024
·
6 min read
Biotech Beach
Sientra to Present at the Stifel 2023 Healthcare Conference
Sientra, Inc. today announced its participation at the Stifel 2023 Healthcare Conference.
November 8, 2023
·
1 min read
Business
Sientra Reports Third Quarter Financial and Operational Results
Sientra, Inc., a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced its financial results for the third quarter that ended September 30, 2023.
November 9, 2023
·
18 min read
Business
Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook
Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023.
October 30, 2023
·
8 min read
Business
Sientra Reports Record Second Quarter Financial and Operational Results
Sientra, Inc., a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced its financial results for the second quarter that ended June 30, 2023.
August 10, 2023
·
18 min read
Biotech Beach
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 30, 2023
Sientra, Inc. announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees.
June 30, 2023
·
4 min read
Business
Sientra Announces Appointment of Alexander W. Casdin to Board of Directors
Sientra, Inc. announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023.
June 20, 2023
·
6 min read
Business
Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023
Sientra, Inc., a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023.
July 27, 2023
·
1 min read
FDA
Sientra Announces FDA-Clearance of Novel Portfinder™ Technology
Sientra, Inc. announced that the Food and Drug Administration (FDA) has granted a 510(k) clearance for the Company’s novel Portfinder™ technology.
May 17, 2023
·
5 min read
Biotech Beach
Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander
Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510k-clearance for the Company’s novel, patented1 AlloX2 Pro Tissue Expander.
June 8, 2023
·
6 min read
1 of 68,626
Next
